Skip to content
value.today

Pro-Dex, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2025–FY2026 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 18.9% a year (statements).

%

US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2026 (statements); negative means more cash than debt.

What today's price assumes

A market value of $199 M means free cash flow growing 30.9% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.

Revenue grew 18.9% a year over the last three years.

Cash-flow value of the shares
$79 M
-60% against the market value
Value of the whole business
$89 M
before net debt
Value from after year 10
66%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →13.94%16.44%18.94%21.44%23.94%
7.92%-60%-51%-39%-26%-10%
8.92%-68%-61%-51%-41%-28%
9.92%-74%-68%-60%-51%-41%
10.92%-78%-73%-67%-59%-50%
11.92%-81%-77%-72%-65%-58%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Medical Instruments: $335 M to $837 M, median $579 MPrice to salesPrice to sales of Medical Instruments: $152 M to $514 M, median $269 MPrice to bookPrice to book of Medical Instruments: $94 M to $315 M, median $212 MCash-flow value$0 M$226 M$452 M$678 M$904 MMarket value $199 M

Your own DCF model

A full discounted-cash-flow model of Pro-Dex, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Instruments

Multiples of its companies with a market value at most 60 days old, times Pro-Dex, Inc.'s own figures of FY2026.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Pro-Dex, Inc.Applied toValue (25th to 75th)Companies
P/E24.5× / 42.4× / 61.3×16.6×net income $14 M$335 M to $837 M15
Price to sales2.0× / 3.5× / 6.6×2.5×revenue $78 M$152 M to $514 M23
Price to book2.0× / 4.4× / 6.6×4.2×book equity $48 M$94 M to $315 M23

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Pro-Dex, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

14.6×

Now below its median of 15.6×; range 9.3× to 74.6× over 29 months.

0×19×37×56×75×2020202120222023202420252026P/E 15×Median 16×

Price to sales

2.6×

Now above its median of 2.4×; range 1.4× to 3.5× over 29 months.

0×1×2×3×4×2020202120222023202420252026Price to sales 3×Median 2×

Price to book

4.2×

Now below its median of 4.5×; range 2.1× to 6.8× over 29 months.

0×2×3×5×7×2020202120222023202420252026Price to book 4×Median 5×

as of Oct 28, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 28, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2026to Jun 30, 2026$78 M$14 M$7 M$0 M$7 M$9 MSEC annual report (10-K, 20-F)
FY2025to Jun 30, 2025$67 M$9 M$-2 M$1 M$-3 M$15 MSEC annual report (10-K, 20-F)
FY2024to Jun 30, 2024$54 M$2 M$6 M——$9 MSEC annual report (10-K, 20-F)
FY2023to Jun 30, 2023$46 M$7 M$5 M——$10 MSEC annual report (10-K, 20-F)
FY2022to Jun 30, 2022$42 M$5 M$-1 M$2 M$-2 M$13 MSEC annual report (10-K, 20-F)
FY2021to Jun 30, 2021$38 M$6 M$-2 M$2 M$-4 M$9 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $199 M on Oct 28, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.